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Abstract. 
 
Teratomas are benign tumors that form after 
ectopic injection of embryonic stem (ES) cells into mice 
and contain derivatives of all primitive germ layers. To 
study the role of 
 
b
 
1 integrin during teratoma formation, 
we compared teratomas induced by normal and 
 
b
 
1-null 
ES cells. Injection of normal ES cells gave rise to large 
teratomas. In contrast, 
 
b
 
1-null ES cells either did not 
grow or formed small teratomas with an average weight 
of 
 
,
 
5% of that of normal teratomas. Histological anal-
ysis of 
 
b
 
1-null teratomas revealed the presence of vari-
ous differentiated cells, however, a much lower number 
of host-derived stromal cells than in normal teratomas. 
Fibronectin, collagen I, and nidogen were expressed 
but, in contrast to normal teratomas, diffusely deposited 
in 
 
b
 
1-null teratomas. Basement membranes were present 
but with irregular shape and detached from the cell 
surface.
Normal teratomas had large blood vessels with a 
smooth inner surface, containing both host- and ES 
cell–derived endothelial cells. In contrast, 
 
b
 
1-null terato-
mas had small vessels that were loosely embedded into 
the connective tissue. Furthermore, endothelial cells 
were always of host-derived origin and formed blood 
vessels with an irregular inner surface. Although 
 
b
 
1-
deficient endothelial cells were absent in teratomas, 
 
b
 
1-
null ES cells could differentiate in vitro into endothelial 
cells. The formation of a complex vasculature, however, 
was significantly delayed and of poor quality in 
 
b
 
1-null 
embryoid bodies. Moreover, while vascular endothelial 
growth factor induced proliferation of endothelial cells 
as well as an extensive branching of blood vessels in 
normal embryoid bodies, it had no effect in 
 
b
 
1-null em-
bryoid bodies.
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1. 
 
Abbreviations used in this paper
 
: BrdU, bromodeoxyuridine; ECM, ex-
tracellular matrix; ES, embryonic stem; PECAM, platelet/endothelial cell
adhesion molecule; VEGF, vascular endothelial growth factor; vWF, von
Willebrand Factor.
 
A
 
 hallmark of tumor cells is their ability to grow an-
chorage independent. Proliferation and survival of
tumor cells, determining progression of solid tu-
mors, are independent of signals elicited by interactions
with the surrounding extracellular matrix (ECM
 
1
 
; Folk-
man and Moscona, 1978). In contrast, normal diploid cells
require anchorage to the ECM for proliferation as well as
survival (Dike and Farmer, 1988). Several lines of direct
evidence show that integrins transduce these signals (Var-
ner and Cheresh, 1996).
Integrins are the most important family of cell surface
receptors that mediate cell–matrix interactions (Hynes,
1992). They are heterodimers of noncovalently linked 
 
a
 
and 
 
b
 
 subunits. So far 15 different 
 
a
 
 subunits and 8 differ-
ent 
 
b
 
 subunits are known. The 
 
b
 
1 subunit can associate
with at least 10 different 
 
a
 
 subunits forming the largest
subfamily of integrins. Members of the 
 
b
 
1 integrin sub-
family primarily bind to components of the ECM such as
fibronectin, collagens, and laminins, but some of them also
participate in direct cell–cell adhesion (Hynes, 1992; Haas
and Plow, 1994). The cytoplasmic domain of 
 
b
 
1 integrin
can directly interact with cytoskeletal proteins such as
talin and 
 
a
 
-actinin and with signal transducing proteins
such as focal adhesion kinase (FAK; Schaller et al., 1995)
and integrin-linked kinase (Hannigan et al., 1996).
Integrin engagement and clustering regulate shape, mo-
tility, survival, and proliferation of cells. These events are
executed by integrin-mediated cascades of intracellular
signals that include tyrosine phosphorylation of FAK
(Guan and Shalloway, 1992), increases in intracellular
Ca
 
2
 
1
 
 levels (Schwartz, 1993), intracellular pH (Schwartz et
al., 1989, 1990), inositol lipid synthesis (McNamee et al.,
1993), and expression of cyclins (Guadagno et al., 1993).
Furthermore, it has been demonstrated that integrins can
also mediate the activation of protein kinase C (Vuori and
Ruoslahti, 1993), mitogen-activated protein kinase (Mor-
ino et al., 1995) and NF-
 
k
 
B (Yebra et al., 1995). In addi-
tion to these adhesion-mediated signaling pathways, many
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cells depend on growth factor–mediated signals for appro-
priate cell cycle progression and proliferation.
In the present study we have used 
 
b
 
1 integrin–deficient
embryonic stem (ES) cells (Fässler al., 1995) to induce ter-
atomas in syngeneic mice. ES cells as well as pre- or early
postimplantation embryos of most mouse strains develop
into tumors when transplanted into an ectopic location of
syngeneic animals (Damjanov and Solter, 1974; Dam-
janov, 1978). These tumors are composed of various dif-
ferentiated somatic tissues and are called teratomas. We
show that 
 
b
 
1-null ES cells give rise to either very small or
no teratomas. The most prominent changes that are asso-
ciated with the impaired growth in 
 
b
 
1-null teratomas are
abnormal depositon of ECM proteins and various defects
in basement membranes. Furthermore, 
 
b
 
1-null teratomas
showed an inefficient angiogenesis. A number of studies
have demonstrated convincingly that tumor growth is de-
pendent on angiogenesis (Folkman, 1996). Tumor angio-
genesis is regulated by factors produced by tumor cells as
well as by cell adhesion molecules expressed on endothe-
lial cells. Systemic or local administration of antibodies or
cyclic RGD peptides blocking 
 
a
 
v
 
b
 
3 integrin function in-
hibits tumor angiogenesis and as a consequence promotes
tumor regression (Brooks et al., 1994
 
a
 
). This anti-angio-
genic effect of the 
 
a
 
v
 
b
 
3 antagonists results from the acti-
vation of apoptosis of newly sprouting blood vessels
(Brooks et al., 1994
 
b
 
). We now show that 
 
b
 
1 integrin plays
an essential role during angiogenesis in teratomas. In nor-
mal teratomas both host- and ES cell–derived endothelial
cells contribute to angiogenesis. In contrast, in 
 
b
 
1-null ter-
atomas, all vascular cells are exclusively derived from the
host. Furthermore, we report that vascular endothelial
growth factor (VEGF) treatment–induced proliferation of
endothelial cells and extensive branching of blood vessels
in normal but not in 
 
b
 
1-null embryoid bodies.
 
Materials and Methods
 
Cells and Cell Culture
 
The following ES cells were used to induce teratomas: wild-type ES cell
line D3 (
 
1
 
/
 
1
 
; Doetschman et al., 1985); G119 (
 
1
 
/
 
2
 
), which is heterozy-
gous for the 
 
b
 
1 integrin gene mutation; G101 (
 
1
 
/
 
1
 
), which is wild-type for
 
b
 
1 integrin gene but mock transfected; and G201 (
 
2
 
/
 
2
 
) which is 
 
b
 
1 inte-
grin deficient (Fässler et al., 1995). In the cell clones G119 and G201, a fu-
sion DNA of 
 
b
 
-galactosidase and neomycin is inserted in frame with the
ATG of the 
 
b
 
1 integrin gene (Fässler et al., 1995). The cell clone G101
contains a randomly integrated 
 
b
 
-galactosidase gene that is ubiquitously
expressed.
ES cells were cultured in the absence of a fibroblast feeder layer in
DME, supplemented with 20% heat-inactivated FCS (GIBCO BRL,
Gaithersburg, MD), 0.1 mM 
 
b
 
-mercaptoethanol (Sigma Chemical Co., St.
Louis, MO), 1
 
3
 
 non-essential amino acids (GIBCO BRL), and 1,000 U/ml
recombinant leukemia inhibiting factor (GIBCO BRL).
For differentiation, ES cells were cultured in hanging drops as de-
scribed previously (Fässler et al., 1996). Briefly, 600 cells were cultured in
20 
 
m
 
l of DME, supplemented with 20% FCS hanging from the lid of the
culture dish for 5 d, which allows the formation of cell aggregates (embry-
oid bodies). Subsequently, the aggregates were plated on Tissue Tek
chambers (Nunc, Wiesbaden, Germany) and incubated for 7, 15, or 20 d,
respectively, fixed in 4% paraformaldehyde and immunostained for von
Willebrand Factor (Behringwerke Ag, Marburg Lahn, Germany) and
platelet endothelial cell adhesion molecule (PECAM) (Vecchi et al.,
1994).
Alternatively, after outgrowth of cell aggregates for 20 d, cells were
trypsinized and cultured on gelatin-coated glass cover slips for 24 h, fixed,
and stained for von Willebrand Factor (vWF) or PECAM. Positive cells
were counted using an Axiophot fluorescence microscope (Carl Zeiss,
Oberkochen, Germany).
For VEGF treatment, ES cells were cultured in hanging drops for 2 d,
in bacteriological dishes for 3 d, and then plated on gelatinized glass cover
slips for another 12 d. The culture medium was DME, containing 20%
FCS with either 10 or 20 ng/ml VEGF (R&D Sytems, Wiesbaden, Ger-
many).
 
Antibodies
 
The following primary antibodies were used: rabbit anti–rat 
 
b
 
1 integrin;
hamster anti–mouse 
 
b
 
3 integrin; hamster anti–mouse 
 
a
 
v integrin (both
from PharMingen, San Diego, CA); hen anti–human FN (Johansson and
Höök, 1984); rabbit anti–mouse FN (GIBCO BRL); goat anti-collagen
type I; goat anti-collagen type III (both from Southern Biotechnology As-
sociates Inc., Birmingham, AL); rat anti–mouse nidogen (Dziadek et al.,
1988); rat anti–mouse PECAM-1 (Vecchi et al., 1994); and rabbit anti–
mouse vWF (Behringwerke).
The following secondary antibodies were used: goat anti–rabbit FITC;
goat anti–rabbit Cy3; rabbit anti–hamster FITC; goat anti–chicken FITC;
donkey anti–goat Cy3; goat anti–rat Cy3 (Jackson Immunoresearch Lab.
Inc., West Grove, PA), rabbit anti-digoxygenin FITC (Boehringer Mann-
heim, Mannheim, Germany), biotinylated goat anti–rabbit Ig (Vector
Laboratories, Inc., Burlingame, CA), biotinylated goat anti–rat Ig (Amer-
sham Intl., Little Chalfont, UK), and streptavidin-horseradish peroxidase
conjugate (Amersham Intl.).
 
Teratoma Induction
 
10
 
7
 
 ES cells were trypsinized, washed twice, suspended in 100 
 
m
 
l PBS, and
then injected subcutaneously on the back of syngeneic 129/SV male mice.
After 21 or 28 d, tumors were surgically removed and frozen in ice-cold
isopentan. To analyze cell proliferation, 25 mg per 100 g body weight of
the thymidine analogue bromodeoxyuridine (BrdU) was injected intra-
peritoneally 2.5 h before the excision of the tumors.
 
Microscopical Analysis of Embryoid Bodies 
and Tumor Tissue
 
Light microscopy.  
 
For light microscopical examination, small pieces of ter-
atomas and 20-
 
m
 
m-thick immunostained cryosections were dehydrated
conventionally in a graded ethanol series, and finally infiltrated with and
embedded in araldite (Serva, Heidelberg, Germany). Semithin sections of
1–2 
 
m
 
m were analyzed using a Zeiss Axiophot microscope (Carl Zeiss),
with or without methylene blue staining.
 
Histochemistry.  
 
Teratomas were surgically removed, frozen in ice-cold
isopentan, and stored at 
 
2
 
80
 
8
 
C. Tissue specimens were cut into 10-
 
m
 
m-thick
sections and collected on glass slides (Shandon, Frankfurt, Germany). He-
matoxylin/Eosin and lacZ staining followed published protocols (Fässler
et al., 1995). Stained sections were analyzed using a Zeiss Axiophot micro-
scope.
 
Cell proliferation.  
 
Incorporation of intraperitoneally injected BrdU
into the DNA of replicating teratoma cells was analyzed using anti-BrdU
monoclonal antibodies, following the protocol supplied by the manufac-
turer (Boehringer Mannheim).
Similarly, proliferation of cells in embryoid bodies was assayed after
addition of BrdU to the culture medium and incubation for another 2 h.
Embryoid bodies were fixed as described above, and then processed fol-
lowing the manufacturer’s protocol. For development of the immuno-
staining 3,3-diaminobenzidine-tetrahydrochloride (DAB) with nickel en-
hancer (12 
 
m
 
l 0.1 PBS, 300 
 
m
 
l DAB, 300 
 
m
 
m NH
 
4
 
Cl, 300 
 
m
 
l NiSO
 
4
 
, 10%
glucose, and 50 
 
m
 
l glucose oxidase) was used. This gives rise to a black re-
action product that is localized in the nuclei of proliferating cells. Subse-
quently, sections were incubated with vWF antibody or PECAM-1 anti-
body (1:800) and processed as described below. Counterstaining was done
with methyl green for 35 s. Afterwards, embryoid bodies were dehydrated
in a graded ethanol series, coverslipped, and analyzed using a Zeiss Axio-
phot microscope.
 
Apoptosis.  
 
Cell death was analyzed following the protocol supplied by
the manufacturer (Oncor, Heidelberg, Germany). Briefly, tissue sections
were fixed in 4% paraformaldehyde in PBS, postfixed in ethanol/acetic
acid (2:1), and incubated with terminal deoxynucleotidyl transferase,
which catalyzes the addition of digoxygenin-conjugated nucleotides to
free 3
 
9
 
-hydroxyl groups in apoptotic cells. Incorporation of labeled nucle-
otides was detected by FITC-conjugated, anti-digoxygenin antibodies. 
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The number of apoptotic cells was determined from random sections of
three normal and four 
 
b
 
1-null teratomas.
 
Immunofluorescence.  
 
Tumor sections, which were 6-
 
m
 
m thick, were in-
cubated with primary antibody in PBS, supplemented with 1% BSA at di-
lutions recommended by the suppliers for 1 h, at room temperature. Sub-
sequently, the sections were washed three times in PBS and incubated
with fluorescence-labeled secondary antibodies at dilutions recommended
by the manufacturer for 1 h, at room temperature. After washing three
times in PBS, the fluorescent specimens were mounted using elvanol
(Fässler et al., 1995).
For analyzing the expression of 
 
a
 
v and 
 
b
 
3 integrin on endothelial cells,
embryoid bodies were fixed in 4% paraformaldehyde and indirectly dou-
ble labeled with hamster antibodies against 
 
a
 
v or 
 
b
 
3 integrin (PharMin-
gen), respectively, and rat antibodies against PECAM-1 (Vecchi et al.,
1994). Subsequently, embryoid bodies were washed three times in PBS
and incubated with fluorescence-labeled secondary antibodies at dilutions
recommended by the manufacturer for 1 h at room temperature. After
washing three times in PBS, the fluorescent specimens were mounted us-
ing elvanol (Fässler et al., 1995). Analysis was performed using a Zeiss
Axiophot fluorescence microscope.
 
Immunohistochemistry.  
 
For immunohistochemistry, 20-
 
m
 
m-thick cryo-
sections of sucrose-embedded teratomas prefixed with 4% paraformalde-
hyde in 0.1
 
3
 
 PBS, and paraformaldehyde-fixed embryoid bodies were
stained. Endogenous peroxidase was blocked by 3% H
 
2
 
O
 
2
 
 in 60% metha-
nol. Subsequently, cells were permeabilized with 0.2% Triton X-100
(Sigma Chemical Co.) in 0.1
 
3
 
 PBS. The sections were incubated with von
Willebrand antibody (1:1,000) or PECAM antibody (1:800) in PBS. Em-
bryoid bodies were incubated in PBS, supplemented with 0.8% BSA over-
night at 4
 
8
 
C. Subsequent sections and embryoid bodies were washed four
times in PBS and incubated with biotinylated secondary antibodies for 1 h
at room temperature. A streptavidin–horseradish peroxidase complex was
then used as a detection system (1:200; incubation for 1 h at room temper-
ature). The staining was developed for 15 min with DAB in 5 mM Tris-
HCl buffer, pH 7.4, supplemented with 0.1% H
 
2
 
O
 
2
 
. Analysis was per-
formed using a Zeiss Axiophot microscope. Morphometrical analyses of
vessels identified by PECAM antibody were performed with Optimas 5.2
(Optimas Corporation, Bothwell, WA).
 
Electron Microscopy
 
Tumor tissue was obtained from 6-wk-old chimeric animals, which were
killed by cervical dislocation and subsequently transcardially perfused
with a 0.1 mol/liter cacodylate buffer containing 2% paraformaldehyde
and 2% glutaraldehyde at a perfusion pressure of 60 cm H
 
2
 
O. Tumors
were removed, fixed for an additional 4 h in the same fixative, and then
cut into small pieces and fixed in 0.1 mol/liter cacodylate buffer, pH 7.3,
containing 2% osmium tetroxide for 2 h at 4
 
8
 
C. Tissue pieces were rinsed
three times in cacodylate buffer, block stained for 8 h in 70% ethanol con-
taining 1% uranyl acetate, dehydrated in a series of graded ethanol, and
embedded in araldite. Ultrathin sections (30–60 nm) obtained with a dia-
mond knife on a Reichert ultramicrotome (Reichert, Bensheim, Ger-
many) were placed on copper grids and examined with a Zeiss EM 902A
electron microscope.
Embryoid bodies were fixed in a 100 mM Hepes/Pipes buffer, pH 7.35,
containing 1.75% paraformaldehyde, 2% glutaraldehyde, and 15% picric
acid for 1 h at room temperature. Afterwards embryoid bodies were
treated with 100 mM Hepes/Pipes buffer containing 1% tannic acid for 30
min at room temperature and finally osmificated with 0.5% OsO
 
4
 
. Before
embedding in Epon resin (Agar Scientific, Stansted, UK) embryoid bod-
ies were dehydrated in a graded series of ethanol. For light microscopy,
semithin sections were stained with methylene blue. For electron micros-
copy, ultrathin sections (30–60 nm) were mounted on formvar-coated cop-
per grids, stained with 0.2% uranyl acetate and lead citrate, and then ex-
amined with a Zeiss EM 902A electron microscope.
 
Results
 
ES Cells Lacking 
 
b
 
1 Integrin Form No or
Only Small Teratomas
 
To test whether the lack of 
 
b
 
1 integrin has an influence on
the development of teratomas normal and 
 
b
 
1-null ES cells
were injected subcutaneously into syngeneic male mice.
After 21 d of incubation, wild-type tumors were clearly
visible on the back of the mice. In contrast, 
 
b
 
1-null tumors
either did not form or were significantly reduced in size
(Fig. 1).
To investigate the growth of 
 
b
 
1-null tumors in more de-
tail, mice were killed by cervical dislocation and examined
under the stereomicroscope. In 9 out of 18 animals injected
with 
 
b
 
1-null ES cells, no tumor could be detected either at
the site of injection, or in distant organs. In the remaining
nine animals, a small tumor had formed, which was signifi-
cantly reduced in weight (mean value 47 mg) when com-
pared with tumors derived from normal (0.93 g) or 
 
b
 
1 inte-
grin–heterozygous (1.18 g) ES cells (Fig. 2). No difference
in tumor growth was observed in mice carrying either a
 
b
 
1-null tumor alone or together with a normal or heterozy-
gous tumor.
Figure 1. Male 129/Sv mice inoculated with 107 D3 cells (b11/1;
right side of the back) and 107 G 201 cells (b12/2, left side of the
back). The right side of the back was inoculated with normal ES
cells. After an incubation period of 3 wk, both mice developed a
big teratoma (arrows). The left side of the back was inoculated
with b1-null ES cells. Note that a small teratoma formed and is
visible in the left mouse (arrowheads) but not in the right mouse.
Figure 2. Weights of terato-
mas derived from normal (1/1),
b1-heterozygous (1/2), and
b1-null (2/2) ES cells. The
mean values were calculated
from 13 1/1, 4 1/2, and 9
2/2 teratomas, respectively.
Individual values are desig-
nated by an x.The Journal of Cell Biology, Volume 139, 1997 268
Figure 3. Analysis of cell
proliferation and apoptosis
in a normal (1/1) teratoma
and a b1-null (2/2) ter-
atoma. ES cells were injected
under the skin of the back
and incubated for 21 d. 2 h
before tumor isolation BrdU
was injected intraperito-
neally. Incorporated BrdU
was detected using specific
antibodies labeled with FITC
(A and B). Apoptotic cells
were identified by staining
for the presence of free 39-
hydroxyl groups in tissue sec-
tions of 1/1 and 2/2 terato-
mas (C and D). Bar, 100 mm.
Figure 4. Histology of normal (1/1) and b1-null (2/2) teratomas. Tumors derived from normal ES cells (b1 1/1) and from b1-null ES
cells (b1 2/2) were stained with Hematoxylin/Eosin (A and B) and lacZ/eosin (C and D), respectively. Blue, lacZ-positive cells are ES
cell-derived whereas lacZ-negative cells are host-derived stromal cells that have migrated into the tumor tissue. Stars indicate lumina of
glandular structures. Bar, 100 mm.Bloch et al. b1 Integrin and Teratoma Growth 269
Cell Proliferation and Apoptosis Is Not Significantly 
Altered in b1-null Teratomas
To test whether cell proliferation is reduced in b1-null tu-
mors BrdU was injected into tumor-bearing mice. Detec-
tion of BrdU in tissue sections with specific antibodies
showed that the distribution of replicating cells is similar
in normal and b1-null teratomas. Some areas in both tu-
mor types contained nests of many proliferating cells,
whereas other areas show a homogenous distribution of a
few proliferating cells (Fig. 3). This heterogeneity of the
tumor architecture results from the wide range of different
tissues that form in teratomas. As a consequence, the
number of proliferating as well as apoptotic cells varied
tremendously from one area to another; normal tumors
grown for 10 d had between 84 and 176 BrdU-postive cells
per mm2 tissue section and tumors grown for 21 d had be-
tween 220 and 279 BrdU-positive cells per mm2 tissue sec-
tion. In corresponding sections of b1-null teratomas, the
number of proliferating cells ranged between 42 and 116
cells in 10-d-old teratomas, and between 156 and 265 cells
in 21-d-old teratomas. This large range in proliferating
cells in both tumor types did not provide a statistically sig-
nificant difference but a tendency towards a reduced pro-
liferation rate in b1-null teratomas.
Similarly, the number of apoptotic cells was very inho-
mogenously distributed in the tissue of normal and b1-null
teratomas: b11/1, b11/2, and b12/2 teratomas showed
higher apoptosis rates in areas that were lacZ-positive, and
thus ES cell–derived and lower rates in areas that were
lacZ-negative, and thus host cell–derived (data not shown).
Both tumor types showed areas with small cell clusters
with a high rate of apoptosis, whereas in other areas the
apoptotic cells were evenly distributed (Fig. 3). The num-
ber of apoptotic cells ranged between 250 and 712 cells per
mm2 tissue in normal teratomas, and between 249 and 805
cells per mm2 tissue section in b1-null teratomas. Also
here, the large variation did not provide a statistically sig-
nificant difference but again a tendency towards a higher
apoptosis rate in b1-null teratomas was apparent.
b1-Null Teratomas Contain Differentiated Cells
but Have an Altered Tissue Architecture with Less
Host-derived Cells
Hematoxylin/Eosin staining revealed that b1 1/1 terato-
mas (G101) (Fig. 4 A) and b1 1/2 teratomas (not shown)
are composed of a variety of differentiated cells and tis-
sues, e.g., glandular epithelium, cartilage, connective tissue,
and neuronal cells. b1-Null tumors appeared cell dense
Figure 5. Immunostaining for
ECM components in normal
(1/1) and in b1-null (2/2)
teratomas. The antibodies
used were directed against
b1 integrin (A and B), fi-
bronectin (C and D), and col-
lagen I (E and F). The stain-
ing shown in A and C, and B
and D, respectively, are dou-
ble stainings of the same tis-
sue specimens. Arrows indi-
cate dense cords of connective
tissue. Bar, 100 mm.The Journal of Cell Biology, Volume 139, 1997 270
and contained fewer cords of fibrotic material (Fig. 4 B).
Histochemical analysis of several b1-null tumors revealed
that many differentiated cells are present in b1-null terato-
mas. ES cell–derived cells could be differentiated by lacZ
activity, since the lacZ gene was introduced in the b1 inte-
grin gene and in the genome of the mock-transfected ES
cells (Fässler et al., 1995; and data not shown). Mock-
transfected, as well as b1 integrin–heterozygous tumors
contained large areas devoid of lacZ activity proving their
host-derived origin (Fig. 4 C). In contrast, the number of
lacZ-negative cells was low in all b1-null tumors analyzed
(Fig. 4 D) indicating that the migration of normal host
cells into mutant tumor tissue is reduced.
Deposition of Extracellular Proteins Is Altered in
b1-null Teratomas
To test whether the deposition of matrix proteins is affected
by the lack of b1 integrin, the distribution of fibronectin,
collagen I, and nidogen were compared between normal and
b1-null tumors. In normal tumors most of the fibronectin
(Fig. 5 C) was associated with cells expressing large amounts
of b1 integrin (Fig. 5 A). Only in a few areas fibronectin
staining did not colocalize with b1 integrin staining (data
not shown). In b1-null tumors, on the other hand, fibronectin
was deposited throughout the tumor tissue (Fig. 5 D) and
did not correlate with host cell–derived b1 integrin expression
(Fig. 5 B). Similarly, in sections derived from b1-null tumors,
collagen I (Fig. 5 F) and nidogen (not shown) were diffusely
distributed. This was not the case in normal tumors in
which collagen I (Fig. 5 E) and nidogen (not shown) were
mainly restricted to areas with strong b1 integrin staining.
To evaluate whether the ultrastructural morphology of
basement membranes is altered by the lack of b1 integrin
expression, electronmicroscopy was performed with tumor
tissues and embryoid bodies derived from normal and b1-
null ES cells. In normal tumors and normal embryoid bod-
ies the basement membrane was continuously present
along the basal surface of epithelial cells (Fig. 6, A and D)
or around muscle cells (not shown) with a constant width
that never exceeded 30 nm. In contrast, most cells in b1-
null teratomas and embryoid bodies were covered by par-
tially detached basement membranes, which resulted in
the formation of irregular clefts between plasma mem-
brane and lamina densa (Fig. 6, B and F). In other areas,
cells were covered by several layers of basement mem-
branes (Fig. 6 C) or by only partially developed basement
membranes (Fig. 6, E and F).
Figure 6. Electronmicroscopy
of normal (A and D) and b1-
null teratomas and embryoid
bodies (B, C, E, and F). Nor-
mal cells in teratomas (A)
and embryoid bodies (D) are
covered by a smooth base-
ment membrane that is strictly
located in close vicinity of
the cell surface (arrowhead).
In b1-null teratomas as well
as b1-null embryoid bodies,
the basement membranes are
partially detached (B and F,
arrows), multilayered (C), or
show an increased thickness
and a loss of typical structure
(E). Bar, 250 nm.Bloch et al. b1 Integrin and Teratoma Growth 271
Blood Vessels of b1-null Teratomas Are Small
and Irregular in Shape and Lack ES Cell-derived 
Endothelial Cells
Hematoxylin/Eosin staining, as well as immunostaining for
the endothelial markers vWF and PECAM revealed a
large number of circular vessels of various sizes in b1 1/1
teratomas (Fig. 7 A). In contrast, in b1-null tumors, vessels
were smaller in size and of irregular shape (Fig. 7 B).
To test whether b1-null ES cells can contribute to the
formation of blood vessels, endothelial cells were charac-
terized in b1 1/1 and 2/2 teratomas. In b1 1/1 and 1/2
teratomas, all cells that expressed vWF or PECAM showed
strong staining for b1 integrin (Fig. 7 C). Furthermore,
many cells that expressed vWF were also lacZ-positive
(Fig. 8, A and C) clearly indicating that ES cells can con-
tribute to angiogenesis in developing teratomas. In b1-null
tumors, however, cells that expressed vWF (Fig. 7 B) al-
ways expressed high levels of b1 integrin, indicating their
host-derived origin (Fig. 7 D). These results were con-
firmed in serial sections of six b1-null teratomas, which were
analyzed by lacZ and vWF stainings. In all b1-null terato-
mas analyzed so far, cells that were positive for vWF stain-
ing (Fig. 8 B) were negative for lacZ expression (Fig. 8 D).
During the analysis of tissue sections derived from b1-null
teratomas it became evident that also the host cell–derived
vasculature has abnormalities. Whereas blood vessels in
normal teratomas have a smooth inner surface and are
tightly anchored to the surrounding connective tissue (Fig.
9 A), blood vessels in b1-null tumors have an irregular in-
ner surface and display large gaps between endothelial
cells and the surrounding tissue (Fig. 9 B).
b1-Null ES Cells Can Differentiate into Endothelial 
Cells In Vitro but Formation of Vessels Is Delayed
ES cells were cultured for 5 d in suspension to form em-
bryoid bodies, and then were plated on tissue culture
dishes. Initially, PECAM-positive cells were aggregated in
dense clusters (Fig. 10 A). These clusters then started to
form thin tubes and branched. After 7 d on the culture
dish about half of the PECAM-positive cells were part of
blood vessels in embryoid bodies derived from normal ES
cells. After 15 d of incubation, PECAM-positive cell
clumps were no longer visible, the blood vessels were sig-
nificantly grown in diameter, extensively branched (Fig. 10
B), and often contained many blood cells (Fig. 10 C).
When b1-null embryoid bodies were analyzed 7 or 15 d
after plating, only PECAM-positive cell clusters were
found without any signs of vessel formation (Fig. 10 D).
After 20 d in culture, a fine network of small vessels began
to form in some areas of the embryoid bodies (Fig. 10 E).
Figure 7. Immunostaining of a normal (1/1) and a b1-null (2/2) teratoma for the expression of vWF and for b1 integrin expression.
Teratomas were removed 21 d after inoculation and sectioned. Neighboring sections were stained for vWF and b1 integrin expression,
respectively. Whereas normal teratomas have large vessels, b1-null teratomas have small vessels. Note that like in normal tumors vessels
of b1-null tumors coexpress vWF and b1 integrin indicating that endothelial cells are host derived. Bar, 100 mm.The Journal of Cell Biology, Volume 139, 1997 272
Figure 8. Localization of vWF and lacZ expression in normal (1/1) and b1-null (2/2) teratomas. Teratomas were removed 21 d after in-
oculation of ES cells and sectioned. Sections were stained overnight for lacZ expression and subsequently immunostained for vWF ex-
pression. In normal teratomas, vWF-positive areas (A, arrows) are found to be positive and negative for lacZ expression (C, correspond-
ing arrows) indicating that endothelial cells are both host- and ES cell–derived. In contrast, in b1-null teratomas, all vWF-positive areas
(B, arrows) are lacZ-negative (D, corresponding arrows) indicating that endothelial cells are solely host derived. Many other areas, how-
ever, that are vWF-negative (B, arrowhead) are clearly lacZ-positive (D, corresponding arrowhead) indicating that many other regions
in b1-null teratomas are ES cell–derived. Bar, 100 mm.
Figure 9. Semithin sections of a normal and a b1-null teratoma stained with methylene blue and immunostained for vWF. Vessels (V) in
normal teratomas (A) have a smooth inner surface and are tightly embedded within the surrounding tissue (arrows). Vessels of b1-null
teratomas (B) have an irregular surface and have lost contacts to the surrounding tissue (arrows). Bar, 20 mm.Bloch et al. b1 Integrin and Teratoma Growth 273
Figure 10. Normal (1/1) and b1-null (2/2) embryoid bodies immunostained for PECAM. ES cells were differentiated in hanging
drops for 2 d, cultured in bacteriological dishes for another 3 d (which gives a total culture period of 5 d in suspension), and plated on
gelatin-coated cover slips. After various periods on the cover slips (7, 15, 20 d) outgrowth were fixed and stained for PECAM. The cul-
ture periods are designated in each picture. Note the presence of blood cells in vessels of normal embryoid body outgrowths (C). Bars:
(A–D) 80 mm; (F) 40 mm.
These vessels were small in diameter and never contained
blood cells. In other areas, PECAM-positive cells were
still organized in small cell patches, often with loose cell–
cell contacts (Fig. 10 F). The mean value of the diameter
of normal and b1-null vessels in seven embryoid bodies af-
ter a 3-wk culture period was 18.1 6 3.0 mm and 6.8 6 2.1
mm, respectively (Fig. 11).
To determine whether the absence of b1 integrin ex-
pression interferes with the differentiation of endothelial
cells, we counted the number of PECAM-positive cells in
normal as well as b1-null embryoid bodies. After a plating
period of 28 d, 100 embryoid bodies (derived from normal
and b1-null ES cells, respectively) were trypsinized; single
cells were plated and cultured overnight, and then stained for
PECAM expression. Out of 9,600 cells counted, 96 PECAM-
positive cells were found in normal embryoid bodies and 9
cells in b1-null embryoid bodies. This 10-fold decrease of
PECAM-positive cells in the b1-null embryoid bodies in-The Journal of Cell Biology, Volume 139, 1997 274
dicates a delayed or less efficient differentiation of b1-null
endothelial cells.
Expression of b3 and av Integrin Is not Significantly 
Altered on b1-null Endothelial Cells
Proliferating endothelial cells express large amounts of
avb3 and avb5 integrins. To determine whether the ex-
pression of b3 or av integrin is altered on b1-null endothe-
lial cells, normal and b1-null embryoid bodies were dou-
ble-immunostained for either PECAM and b3 integrin
(Fig. 12, A–D), or PECAM and av integrin (Fig. 12, E–H),
respectively. Vessels in embryoid bodies derived from nor-
mal and b1-null ES cells express similar amounts of b3
(Fig. 12, B and D) and av integrin (Fig. 12, F and H).
These data indicate that the absence of b1 integrin is not
associated with an altered expression of other endothelial
cell integrins.
VEGF Does Not Promote Angiogenesis in b1-null 
Embryoid Bodies
VEGF induces proliferation of endothelial cells and sprout-
ing of vessels and therefore is a potent promoter of angio-
genesis. To test whether VEGF can overcome abnormal
angiogenesis in b1-null embryoid bodies, normal and b1
integrin-deficient ES cells were differentiated in the pres-
ence of 10 or 20 ng/ml VEGF, respectively. After 5 d in
suspension culture and 12 d on gelatinized cover slips, em-
bryoid bodies were treated with BrdU for 2 h and subse-
quently stained for PECAM expression and BrdU incor-
poration. Treatment of normal embryoid bodies with either
10 or 20 ng/ml VEGF significantly increased the number
and the extent of blood vessel branching (Fig. 13, A and C;
and Table I). In contrast, VEGF at both concentrations
had no significant effect on blood vessel branching in b1-
null embryoid bodies (Fig. 13, B and D; and Table I) indi-
cating that VEGF cannot overcome the lack of b1 integrin
function. VEGF treatment also increased the number of
BrdU-positive cells in normal (Fig. 13, A and C, arrows)
but not in b1-null embryoid bodies (Fig. 13, B and D, ar-
rows).
Discussion
In the present study we show that the growth of ES cell–
derived teratomas is dependent on the expression of b1 in-
tegrin. Whereas subcutaneous injection of normal ES cells
under the skin of the back of syngeneic mice gave rise to
large teratomas, b1-null ES cells either produced no, or
only very small tumors. This reduced growth of b1-null
teratomas suggests a growth-supporting role of b1 inte-
grin.
These results were unexpected since many tumors lack
a5b1 integrin function, a phenomenon that has been
linked with anchorage-independent growth and high tu-
morigenicity (Hirst et al., 1986; Plantefaber and Hynes,
1990; Varner et al., 1995). Conversely, overexpression of
a5b1 integrin in Chinese hamster ovary cells is accompa-
nied by a loss of tumorigenicity and reduced proliferation
in vitro (Giancotti and Ruoslahti, 1990). A similar growth-
suppressing role was recently demonstrated for a2b1 inte-
grin, which is frequently absent in breast cancer cells. Re-
expression of a2b1 integrin in such cells also leads to a
diminution of the malignant phenotype (Zutter et al., 1995).
Several explanations could account for this discrepancy.
First, ES cells are normal embryonal cells that differenti-
ate into many somatic tissues and thus give rise to a tumor
called teratoma (Damjanov and Solter, 1974; Damjanov,
1978). Since these cells are not transformed, they may still
be dependent on anchorage to the extracellular matrix for
growth (Dike and Farmer, 1988) and survival (Meredith et
al., 1993; Boudreau et al., 1995). Integrins execute cell–
matrix interactions and lack of anchorage in b1-null ES
cells could therefore be an explanation for the reduced tu-
mor growth. To test this hypothesis we analyzed cell pro-
liferation by injecting BrdU into teratoma-bearing mice
and stained for apoptosis. Extensive analysis of normal
and b1-null teratomas revealed that cell proliferation and
apoptosis are not significantly affected in b1-null tumors.
It has to be noted, however, that the extents of prolifera-
tion and apoptosis were very different between different
sections of the same tumor, as well as between individual
tumors. This heterogeneity is due to the ability of ES cells
to differentiate into a wide range of somatic tissues with
different apoptosis and proliferation rates. For this reason
we obtained, in normal as well as b1-null teratomas, enor-
mous variations in the numbers of proliferating and apop-
totic cells. Despite this variation, there were more areas
with higher numbers of proliferating and lower numbers
of apoptotic cells in normal teratomas when compared
with  b1-null teratomas. Such alterations would be in agree-
ment with reports that have linked cell survival with inte-
grin function (for review see Ruoslahti and Reed, 1994).
The binding of a5b1 integrin to fibronectin is inducing bcl-2
Figure 11. Diameter of vessel lumen in normal (1/1) and b1-null
(2/2) embryoid bodies. d, 2/2 PECAM1; h, 1/1 PECAM1.
Morphometrical analysis of PECAM-positive vessels after 5 1 20 d
in culture. Normal embryoid bodies have variously sized vessels
with diam up to 70 mm. In b1-null embryoid bodies most vessels
have a diam of 10 mm and only a few are larger.Bloch et al. b1 Integrin and Teratoma Growth 275
Figure 12. Double immunostaining of
normal (1/1) and b1-null (2/2) embry-
oid bodies for b3 integrin and PECAM
(A–D), and av integrin and PECAM
(E–H). Normal and mutant ES cells
were differentiated for 20 d, fixed and
stained for PECAM (A and C, red) and b3
(B and D, green), or PECAM (E and G,
red) and av (F and H, green), respec-
tively. In normal embryoid bodies large
vessels stain for PECAM (A and C) and
b3 (B), or av integrin (D). In b1-null
embryoid bodies the vessel diameters
are smaller but the staining for PECAM
(E and G), b3 (D), and av (H) is similar,
like in normal bodies. Note the high
background for av staining, which is ex-
pressed on many PECAM-negative cells
in the embryoid bodies. Bar, 15 mm.
Table I. Quantification of Branches of Blood Vessels in Normal 
(1/1) and b1-null (2/2) Embryoid Bodies Treated Without 
or With VEGF
Without VEGF 10 ng/ml VEGF 20 ng/ml VEGF
(1/1) 273 6 103 (n 5 9) 363 6 103 (n 5 8) 372 6 86 (n 5 7)
(2/2) 41 6 30 (n 5 10) 32 6 20 (n 5 8) 76 6 85 (n 5 7)
Embryoid bodies were cultured 5 d in suspension and 12 d on gelatinized glass cover
slips in the absence or presence of 10 or 20 ng/ml VEGF, respectively. After the end
of the culture period, embryoid bodies were fixed and stained for PECAM expression.
Data show all vessel branches per embryoid body and are expressed in mean 1 SD. n
is number of embryoid bodies analyzed.
expression, which is one of the best studied cell survival
factors (Zhang et al., 1995). Other studies showed that dis-
rupting the binding to basement membranes can induce
apoptosis (Boudreau et al., 1995; Coucouvanis and Martin,
1995). Biochemical studies of b1-null teratomas (Sasaki,
T., E. Forsberg, W. Bloch, K. Addicks, R. Fässler, and R.
Timpl, submitted for publication), together with our elec-
tronmicroscopical analysis indicate that the integrity of
basement membranes is severely affected by the absence
of b1 integrin. Whereas epithelial cells of normal terato-
mas are tightly attached to a basement membrane, b1-null
cells have either partly or completely lost this tight attach-
ment leading to the dislocation of basement membranes
into the interstitium. This absence of normal interaction
between cells and basement membranes could not only ex-
plain the increased cell death in teratomas, but also the al-
tered differentiation of keratinocytes (Bagutti et al., 1996)
and cardiac muscle cells (Fässler et al., 1996). Similar de-
fects in basement membrane morphology have been re-
ported in a3-null mice, which have disorganized and frag-
mented glomerular basement membranes, and podocytes
that completely lack foot processes (Kreidberg et al.,
1996). In addition, these mice develop skin blisters that areThe Journal of Cell Biology, Volume 139, 1997 276Bloch et al. b1 Integrin and Teratoma Growth 277
due to an inefficient maintenance of the epidermal base-
ment membrane (DiPersio et al., 1997).
A second explanation for the reduced tumor growth
could be the altered composition or distribution of ECM
proteins in b1-null teratomas. The ECM has an important
role as reservoir for growth factors, proteases, and pro-
tease inhibitors (Alexander and Werb, 1991; Nathan and
Sporn, 1991). Basement membranes, for example, can
store and release many growth factors. The various abnor-
malities of basement membranes as seen in b1-null terato-
mas and b1-null embryoid bodies may contribute to the di-
minished growth and to defects in differentiation (Fässler
et al., 1996). In addition, the disturbed matrix deposition
can alter mechanochemical properties, which may reduce
the growth rate of b1-null teratomas (Ingber, 1991). Indeed,
immunostainings for fibronectin and collagens revealed an
altered distribution in b1-null teratomas. In normal ter-
atomas both matrix proteins concentrate in streaklike
structures and often colocalize with high b1 integrin stain-
ing. In contrast, both proteins are diffusely deposited in
b1-null teratomas and never concentrate along b1 inte-
grin-positive, host-derived cells. This striking finding was
also supported by routine histological analysis. Tissue
specimens of b1-null teratomas contained little ECM, with
many mutant and only a few normal, host-derived (lacZ
negative) cells.
A third explanation for the formation of small terato-
mas could be abnormal angiogenesis in the absence of b1
integrin. In contrast to tumors derived from somatic tissue,
the vasculature of teratomas is derived from the host and
from the ES cells (Risau et al., 1988; Vittet et al., 1996).
Immunostaining demonstrated host-derived endothelial
cells expressing b1 integrin in normal as well as b1-null tu-
mors. Whereas lacZ staining indicated ES cell–derived
(lacZ positive) endothelial cells in b1 integrin–heterozy-
gous as well as mock-transfected tumors, no ES cell–derived
endothelial cells were detected in b1-null teratomas. This
complete absence of b1-null endothelial cells is also seen
in the highly vascularized fetal and adult liver of b1-null
chimeric mice (Fässler and Meyer, 1995; Hirsch et al.,
1996). These data suggest, that b1-deficient ES cells either
do not differentiate in vivo into endothelial cells or that
they differentiate into endothelial cells but cannot organize
into blood vessels. A detailed inspection of the vasculature
revealed furthermore that blood vessels were significantly
smaller in b1-null teratomas as compared to normal ter-
atomas, which may result from the small tumor size. In ad-
dition, however, we found that the shape of smaller vessels
is also different in b1-null tumors: the inner surface is ir-
regular and the vessels are loosely embedded into the sur-
rounding tissue. Apparently, even endothelial cells express-
ing b1 integrin are not able to make normal blood vessels
in b1-null teratoma, indicating lack of an essential interac-
tion between endothelial cells and the surrounding cells or
the extracellular matrix.
To test whether the b1-null ES cells have a cell autono-
mous impairment of differentiation into endothelial cells,
we differentiated ES cells into embryoid bodies in vitro
and assessed for the presence of endothelial cells (Fässler
et al., 1996). To our surprise, we found that differentiation
of endothelial cells occurs in normal and b1-null embryoid
bodies. After 12 d (5 d in suspension culture, and 7 d on
plastic surface) normal endothelial cells start to sprout and
to form a large network of vessels of various diameters
that are also often filled with blood cells. In contrast, b1-
null endothelial cells initially form compact cell nests with
tight cell–cell contacts. Only after a culture period of 3 wk,
b1-null endothelial cells start to migrate and to form small
vessels. The ability of b1-null endothelial cells to differen-
tiate may also occur in vivo. This hypothesis is supported
by the presence of b1-null hematopoietic stem cells in chi-
meric mice (Hirsch et al., 1996) that, together with endo-
thelial cells, develop from a common precursor cell called
hemangioblast. Currently, we have no experimental expla-
nation for the complete lack of b1-null endothelial cells
both in teratomas and in livers of chimeric mice (Fässler
and Meyer, 1995), despite the fact that they are readily
formed in vitro. It is possible that the in vitro environment
favors the survival of these cells, which is not the case in
vivo.
An important role for angiogenesis has been reported
for avb3 and avb5 integrins (Varner and Cheresh, 1996).
Immunostaining of b1-null embryoid bodies with antibod-
ies detecting av or b3 integrin clearly revealed that both
integrin subunits are not downregulated. Therefore, we
can exclude that the absence of b1 integrin expression in-
fluences endothelial cell function by altering the expres-
sion of other integrins. Growth factors and angiogenic sig-
nals can upregulate avb3 expression on endothelial cells
and induce blood vessel branching (Brooks et al., 1994a;
Friedlander et al., 1995). Moreover, several growth factors
were shown to exert their angiogenic signals in concert
with endothelial integrins. For example, tumor necrosis
factor-a and basic FGF depend on avb3 integrin, and
VEGF and TGF-a depend on avb5 integrin (Friedlander
et al., 1995). VEGF is the most potent stimulator of
neovascularization by regulating proliferation of endothe-
lial cells and branching of blood vessels. Testing whether
VEGF can override the defective branching of b1-null en-
dothelial cells, we found that VEGF had no effect on b1-
null endothelial cells: neither the proliferation rate nor the
branching could be enhanced in b1-null embryoid bodies.
Endothelial cells in normal embryoid bodies, however, re-
sponded to VEGF by an increased proliferation rate and
by an extensive formation of new vessel branches. These
data demonstrate for the first time that b1 integrins play
an important role during angiogenesis and moreover, that
VEGF signaling depends on the presence of b1 integrin
function. This finding is unexpected since earlier reports
showed that b1 integrin function is not essential for tumor-
Figure 13. VEGF treatment of normal (1/1) and b1-null (2/2) embryoid bodies. Normal or b1-null embryoid bodies were treated ei-
ther without (A and B) or with (C and D) 10 ng/ml VEGF during a period of 5 d in suspension and 12 d on a gelatinized glass cover slip.
2 h before fixation, the cultures were treated with BrdU. Sections were first stained for BrdU incorporation (arrows), then for PECAM-1,
and finally counterstained with methyl green. Note that VEGF treatment increases the branching of blood vessels (C) and the prolifera-
tion rate of PECAM-positive cells in normal (C, arrows) but not in b1-null embryoid bodies (D, arrows). Bar, 100 mm.The Journal of Cell Biology, Volume 139, 1997 278
induced angiogenesis (Brooks et al., 1994b). Brooks et al.
(1994b) treated chicken embryos that were exposed to
various tumors with anti-b1 integrin antibodies and were
unable to influence tumor growth or angiogenesis. One ex-
planation for this discrepancy may be an incomplete inhi-
bition of b1 integrin function with a single injection of
antibodies. An alternative explanation could be the ubiq-
uitous expression of b1 integrin. Antibodies against b1 in-
tegrin find their antigen on almost all cells and may be
eliminated before endothelial cells proliferate and form
new blood vessels.
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